conv.

All stories
HealthQuiet 8d · day 14

Meta-analysis links cefepime to higher mortality than other beta-lactams

Systematic review of 110 trials finds 94.4% probability cefepime raises death risk, but experts urge caution on clinical implications.

newest coverage 7d agosummary written 7d ago9 pieces NewswiresGoogle News

What to know

  • A meta-analysis of 110 trials with 22,000+ patients found a 94.4% probability that cefepime is linked to higher all-cause mortality (6.6% vs 6.2%) compared to other beta-lactam antibiotics, with a number needed to harm of 227.
  • Researchers and clinical experts have not called for discontinuing cefepime, emphasizing that the mortality signal may reflect dosing problems—underdosing reducing efficacy or overdosing causing toxicity—rather than an inherent drug safety flaw.
  • The finding contradicts some recent real-world trials (including ACORN) where cefepime showed no significant mortality difference or even lower mortality than comparators, raising questions about how trial design differences affect the observed signal.
  • Cefepime remains first-line for febrile neutropenia and serious gram-negative infections; experts argue the proper response is optimized dosing and therapeutic drug monitoring, not drug discontinuation.

“That is a dosing problem, and dosing problems are tractable. The proper response is therefore not to strike cefepime from febrile neutropenia guidelines.”

Daniel Uslan, MD, and Ethan Smith, PharmD, UCLA experts · MedPage Today ↗ · Sep 9

Zahra Sohani, MD, PhD Lead researcher, Hôpital Maisonneuve-RosemontDaniel Uslan, MD UCLA infectious disease expertEthan Smith, PharmD UCLA pharmacistDr. Marc SiegelDr. Marc Siegel Fox News senior medical analyst

Meta-analysis links cefepime to higher mortality than other beta-lactams
NY Post

How it unfolded 4 developments, newest first · click a bar or a number to jump articles

Peak 2 pieces in 4h at Sep 10, 10 AM; 9 pieces over 14 days (9 articles) Sep 10, 10 AM — 2 pieces · 2 articles — Newswires 1, Google News 1Sep 10, 2 PM — quietSep 10, 6 PM — quietSep 10, 10 PM — quietSep 11, 2 AM — quietSep 11, 6 AM — quietSep 11, 10 AM — quietSep 11, 2 PM — quietSep 11, 6 PM — quietSep 11, 10 PM — quietSep 12, 2 AM — quietSep 12, 6 AM — quietSep 12, 10 AM — quietSep 12, 2 PM — quietSep 12, 6 PM — quietSep 12, 10 PM — quietSep 13, 2 AM — quietSep 13, 6 AM — quietSep 13, 10 AM — quietSep 13, 2 PM — quietSep 13, 6 PM — quietSep 13, 10 PM — quietSep 14, 2 AM — quietSep 14, 6 AM — 2 pieces · 2 articles — Google News 2Sep 14, 10 AM — quietSep 14, 2 PM — quietSep 14, 6 PM — quietSep 14, 10 PM — quietSep 15, 2 AM — quietSep 15, 6 AM — quietSep 15, 10 AM — quietSep 15, 2 PM — quietSep 15, 6 PM — 2 pieces · 2 articles — Google News 1, Newswires 1Sep 15, 10 PM — quietSep 16, 2 AM — quietSep 16, 6 AM — 1 piece · 1 article — Google News 1Sep 16, 10 AM — 2 pieces · 2 articles — Newswires 1, Google News 1Sep 16, 2 PM — quietSep 16, 6 PM — quietSep 16, 10 PM — quietSep 17, 2 AM — quietSep 17, 6 AM — quietSep 17, 10 AM — quietSep 17, 2 PM — quietSep 17, 6 PM — quietSep 17, 10 PM — quietSep 18, 2 AM — quietSep 18, 6 AM — quietSep 18, 10 AM — quietSep 18, 2 PM — quietSep 18, 6 PM — quietSep 18, 10 PM — quietSep 19, 2 AM — quietSep 19, 6 AM — quietSep 19, 10 AM — quietSep 19, 2 PM — quietSep 19, 6 PM — quietSep 19, 10 PM — quietSep 20, 2 AM — quietSep 20, 6 AM — quietSep 20, 10 AM — quietSep 20, 2 PM — quietSep 20, 6 PM — quietSep 20, 10 PM — quietSep 21, 2 AM — quietSep 21, 6 AM — quietSep 21, 10 AM — quietSep 21, 2 PM — quietSep 21, 6 PM — quietSep 21, 10 PM — quietSep 22, 2 AM — quietSep 22, 6 AM — quietSep 22, 10 AM — quietSep 22, 2 PM — quietSep 22, 6 PM — quietSep 22, 10 PM — quietYesterday, 2 AM — quietYesterday, 6 AM — quietYesterday, 10 AM — quietYesterday, 2 PM — quietYesterday, 6 PM — quietYesterday, 10 PM — quietToday, 2 AM — quiet ◂ 1 earlier234
Sep 11Sep 12Sep 13Sep 14Sep 15Sep 16Sep 17Sep 18Sep 19Sep 20Sep 21Sep 22now · 6:44 AM ET
  1. 4

    Fox News medical analyst emphasizes dosing over drug safety

    Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital that the study highlights the importance of re-reviewing older research, but stressed that the mortality signal likely reflects dosing problems—both underdosing and overdosing—rather than an inherent safety flaw with cefepime itself.

    “A closer review of the data suggests that both underdosing and overdosing — rather than the drug itself — may be more closely linked to poorer outcomes.”
    — Dr. Marc Siegel
    1. 3 outlets Are You Using Cefepime? New Research Links Antibiotic to Higher Death Risk

      first by NCHStats, 7d ago · also NY Post, The Eastleigh Voice

      2 more headlines
    2. 1 outlet Cefepime and Mortality—A Dosing Problem, Not a Drug Problem

      first by jamanetwork.com, 13d ago

  2. 3

    Fox News and NY Post report finding to general audience

    Major news outlets including Fox News and the NY Post published the findings, framing cefepime as a 'common antibiotic linked to higher risk of death' and reaching a broader non-specialist audience. Coverage highlighted that cefepime is used for pneumonia, UTIs, and skin infections.

    1. 1 outlet Common antibiotic linked to higher risk of death in adults, major study finds

      first by Fox News, 8d ago

  3. 2

    Study spreads to mainstream medical and news outlets

    The meta-analysis findings were picked up and distributed by Medical Dialogues and other news aggregators, expanding coverage beyond specialist medical publications to mainstream outlets.

  4. 3 days quiet
  5. 1

    UCLA experts call finding a 'signal, not a verdict'

    Daniel Uslan and Ethan Smith of UCLA's David Geffen School of Medicine published an accompanying editorial cautioning that the trials generating the signal bear limited resemblance to contemporary practice. They cited recent trials including ACORN, which showed no significant mortality difference between cefepime and piperacillin-tazobactam, and other studies where cefepime showed lower mortality than comparators.

    “This is a signal, not a verdict… the trials that generate this signal bear limited resemblance to contemporary practice.”
    — Daniel Uslan, MD, and Ethan Smith, PharmD
  6. background

    Meta-analysis of 110 trials links cefepime to higher mortality — Zahra Sohani and colleagues published a systematic review and meta-analysis in JAMA Network Open examining 110 randomized trials with over 22,000 patients. The analysis found a 94.4% probability of increased all-cause mortality with cefepime (6.6%) versus other beta-lactams (6.2%), with a number needed to harm of 227 across all trials and 111 when limited to 73 peer-reviewed trials.

Also covered reported alongside — the timeline has no entry for these yet

  1. 2 outlets Cefepime Tied to Higher Mortality Odds vs Other Beta-Lactams

    first by MedPage Today, 9d ago · also Medical Dialogues

    1 more headline

and 1 smaller piece